Results 271 to 280 of about 33,910 (293)

HIV Broadly Neutralizing Antibodies: VRC01 and Beyond

2018
Developing an effective prophylaxis HIV-1 vaccine is likely to require the elicitation of broadly neutralizing antibodies (bnAbs). As the HIV-1 envelope (Env) glycoprotein - the sole target of bnAbs - has evolved multiple mechanisms to evade antibody neutralization, the processes for bnAb generation are highly selective and time-consuming.
openaire   +2 more sources

Broadly Neutralizing Antibodies and the Development of Vaccines

JAMA, 2015
Barton F, Haynes, Todd, Bradley
openaire   +2 more sources

Broadly neutralizing antibodies target a haemagglutinin anchor epitope

Nature, 2022
Jenna J Guthmiller, Julianna Han, Henry A Utset   +2 more
exaly  

B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies

Cell Host and Microbe, 2021
Ningbo Jian, David J Leggat, Vincent Dussupt   +2 more
exaly  

Broadly Neutralizing Antibodies

2017
L. Morris, T.A. Moody
openaire   +1 more source

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Nature Reviews Immunology, 2022
Yanjia Chen, Hao Zhou, Huanzhang Zhu
exaly  

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Cell Host and Microbe, 2020
Qiao Wang, Eleftherios Michailidis, Yingpu Yu   +2 more
exaly  

Broadly Neutralizing Antibodies

RCSB Protein Data Bank, 2014
openaire   +1 more source

Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities

Emerging Microbes and Infections, 2020
Yubin Liu, Wei Cao, Taisheng Li
exaly  

Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller

Cell Host and Microbe, 2023
Hugo Mouquet
exaly